This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Percentage of Participants With Malignancies
Timeframe: Months 12 through 72.
Least Squares Means of Measured Glomerular Filtration Rate (GFR) (Iohexol Serum Clearance in Milliliters Per Minute [mL/Min])
Timeframe: Month 36
Percentage of Participants With Progression of Chronic Allograft Lesions at Month 36
Timeframe: Month 36
Kaplan-Meier Analysis of Percentage of Participants With First Biopsy Proven Acute Rejection (BPAR) by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72